CYP3A4 is a major metabolic enzyme that can profoundly affect the oral exposure and clearance of drug candidates, making the design of molecules that avoid excessive CYP3A4 metabolism while retaining favorable drug-like properties a central challenge in early discovery. Traditional medicinal chemistry typically addresses metabolic liability only after candidate structures have been synthesized, a reactive approach that complicates the simultaneous optimization of CYP3A4 sparing, broader ADMET behavior, and synthetic feasibility. To address this, a conceptual generative transformer framework is proposed for designing novel CYP3A4-sparing molecules, capable of producing chemically valid candidates while respecting ADMET and synthetic constraints. The approach involves fine-tuning a transformer-based molecular language model trained on drug-like SMILES using reinforcement learning, with conditional generation guided by property tokens representing CYP3A4-sparing intent, ADMET desirability, and synthetic accessibility preferences. This framework could generate focused candidate libraries predicted to minimize CYP3A4 liability while maintaining favorable pharmacokinetic and synthetic characteristics, which would then be assessed for novelty, chemical diversity, and alignment with the desired design profile. By proposing metabolically resilient molecular starting points, a CYP3A4-sparing generative transformer could support hit-to-lead and lead-optimization decisions, complementing medicinal chemistry expertise without replacing the need for experimental validation.